Abstract Purpose of Review To analyze and compare the effects of epistaxis treatments for
Hereditary Hemorrhagic Telangiectasia (HHT) patients. Recent Findings Of total of 21 …

Background Hereditary hemorrhagic telangiectasia (HHT) is an autosomal dominant
hereditary disorder resulting in vascular dysplasia and formation of arteriovenous …

Objectives The aim of this study (PROSPERO ID: CRD42017081952) was to evaluate
medical treatment for epistaxis from hereditary hemorrhagic telangiectasia (HHT). Data …

Background Hereditary hemorrhagic telangiectasia (HHT) is an autosomal dominant
disease affecting 1 in 5000 individuals. Epistaxis is seen in more than 90% of patients with …

Background: Epistaxis is the most common manifestation of hereditary hemorrhagic
telangiectasia (HHT), affecting approximately 90% of patients at some point during their …

The inhibiting effects of itraconazole, an antifungal drug on vascular endothelial growth
factor (VEGF) have recently been discovered. By inhibiting VEGF, itraconazole has shown …

To date, there is no approved local therapeutic agent for the treatment of epistaxis due to
hereditary hemorrhagic telangiectasia (HHT). Several case reports suggest the topical use …

Importance Epistaxis is a major factor negatively affecting quality of life in patients with
hereditary hemorrhagic telangiectasia (HHT; also known as Osler-Weber-Rendu disease) …

Objective Epistaxis is a primary complaint in 90% to 96% of patients with hereditary
hemorrhagic telangiectasia (HHT). Numerous surgical and medical treatments aim to …

Background Vascular malformations in hereditary hemorrhagic telangiectasia (HHT) lead to
chronic recurrent bleeding, hemorrhage, stroke, heart failure, and liver disease. There is …